ABSTRACT

Objective

We systematically reviewed the evidence of published original research to determine the role of remdesivir in the management of patients with COVID-19 and a moderate-to-severe course of illness.

Methods

A systematic search of articles was conducted in scientific databases, with the latest update in May 2021. This paper systematically reviewed the clinical evidence available (randomized controlled trials, compassionate use studies, and case reports) on the use of remdesivir for patients with moderate or severe COVID-19.

Results

A total of eleven studies were included: four studies based on compassionate use of remdesivir, three randomized, double-blind, placebo-controlled, multicentre trials, three randomized, open-label, phase III trials, and one case report. Clinical improvement and mortality rates in patients who used remdesivir varied across studies.

Conclusion

Given the current evidence, there is insufficient data to confidently recommend the use of remdesivir alone for the treatment of adult hospitalized patients with moderate-to-severe COVID-19. However, remdesivir may be considered along with an anti-inflammatory agent in patients with pneumonia, on oxygen support, provided there is close monitoring of clinical and laboratory parameters and adverse events.

中文翻译：

---

使用瑞德西韦治疗中度至重度 COVID-19 患者：系统评价

摘要

客观的

我们系统地审查了已发表的原始研究的证据，以确定瑞德西韦在治疗 COVID-19 和中度至重度病程患者中的作用。

方法

对科学数据库中的文章进行了系统搜索，最新更新于 2021 年 5 月。本文系统地回顾了有关瑞德西韦用于中度或严重的 COVID-19。

结果

共纳入 11 项研究：4 项基于同情使用瑞德西韦的研究、3 项随机、双盲、安慰剂对照、多中心试验、3 项随机、开放标签、III 期试验和 1 项病例报告。使用瑞德西韦的患者的临床改善和死亡率因研究而异。

结论

鉴于目前的证据，没有足够的数据可以自信地推荐单独使用瑞德西韦来治疗患有中重度 COVID-19 的成年住院患者。但是，如果对临床和实验室参数以及不良事件进行密切监测，则可以考虑在氧气支持下将瑞德西韦与抗炎药一起用于肺炎患者。